Literature DB >> 8107657

Phase II study of carboplatin as a single drug for relapsed Wilms' tumor: experience of the Brazilian Wilms' Tumor Study Group.

B de Camargo1, R Melaragno, N Saba e Silva, N Mendonça, M N Alvares, E Morinaka, A Marques, M P Cusato.   

Abstract

A total of 15 patients with relapsed Wilms' tumor were treated with carboplatin as a single agent. There were six females and nine males, aged between 2 and 9 years (median:5). The treatment consisted of carboplatin given I.V. as a single agent at a dose of 550 mg/m2 over 1 hour every 3 weeks. There were four (26%) complete responses, four (26%) partial responses, one stable disease, and six with progressive disease. In all patients a total of 56 courses were given and the toxicities found were leukopenia and thrombocytopenia. The overall response rate was encouraging and the toxicity was acceptable and reversible.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8107657     DOI: 10.1002/mpo.2950220409

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  7 in total

Review 1.  Clinical pharmacokinetics and dose optimisation of carboplatin.

Authors:  S B Duffull; B A Robinson
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

2.  Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Children's Oncology Group AREN0321 Study.

Authors:  Najat C Daw; Yueh-Yun Chi; John A Kalapurakal; Yeonil Kim; Fredric A Hoffer; James I Geller; Elizabeth J Perlman; Peter F Ehrlich; Elizabeth A Mullen; Anne B Warwick; Paul E Grundy; Arnold C Paulino; Eric Gratias; Deborah Ward; James R Anderson; Geetika Khanna; Brett Tornwall; Conrad V Fernandez; Jeffrey S Dome
Journal:  J Clin Oncol       Date:  2020-03-05       Impact factor: 44.544

3.  Renal function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy, nephrectomy and radiotherapy in children with Wilms tumour.

Authors:  Najat C Daw; David Gregornik; John Rodman; Neyssa Marina; Jianrong Wu; Larry E Kun; Jesse J Jenkins; Valerie McPherson; Judith Wilimas; Deborah P Jones
Journal:  Eur J Cancer       Date:  2008-11-06       Impact factor: 9.162

Review 4.  Current and emerging chemotherapy treatment strategies for Wilms tumor in North America.

Authors:  Eric J Gratias; Jeffrey S Dome
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

5.  Dose-related nephrotoxicity of carboplatin in children.

Authors:  M W English; R Skinner; A D Pearson; L Price; R Wyllie; A W Craft
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

Review 6.  Mapping Pediatric Oncology Clinical Trial Collaborative Groups on the Global Stage.

Authors:  Ajay Major; Monica Palese; Ebru Ermis; Anthony James; Milena Villarroel; Federico Antillon Klussmann; Laila Hessissen; Jennifer Geel; Muhammad Saghir Khan; Rashmi Dalvi; Michael Sullivan; Pamela Kearns; A Lindsay Frazier; Kathy Pritchard-Jones; Akira Nakagawara; Carlos Rodriguez-Galindo; Samuel L Volchenboum
Journal:  JCO Glob Oncol       Date:  2022-02

7.  Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis.

Authors:  M W English; S P Lowis; B Peng; A Boddy; D R Newell; L Price; A D Pearson
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.